Search research articles
Contact Us
Filters
Showing results (101-110 of 125) with videos related to
Page
of 13
Sort By:
The Journal of Pediatrics
|
August 25, 2019
Vascular Health of Children Conceived via In Vitro Fertilization
Wendy Y Zhang, Elif Seda Selamet Tierney, Angela C Chen, et al.
The Journal of Cell Biology
|
September 1, 1984
Abnormality of insulin binding and receptor phosphorylation in an insulin-resistant melanoma cell line
H U Haring, M F White, C R Kahn, et al.
Clinical Rheumatology
|
October 14, 2016
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
R Fleischmann, P J Mease, S Schwartzman, et al.
The Clinical Journal of Pain
|
October 19, 1999
Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain
M E Hale, R Fleischmann, R Salzman, et al.
Clinical Therapeutics
|
November 24, 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group
T J Schnitzer, K Truitt, R Fleischmann, et al.
Journal of the Association for Information Science and Technology
|
October 17, 2022
Trust in COVID-19 public health information
Nitin Verma, Kenneth R Fleischmann, Le Zhou, et al.
Gastroenterology
|
June 1, 1990
A report of three multiclinic trials evaluating arbaprostil in arthritic patients with ASA/NSAID gastric mucosal damage. The Upjohn Company Arbaprostil ASA/NSAID Gastric Mucosal Damage Treatment Study Groups
A R Euler, M Safdi, J Rao, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D van der Heijde, R Fleischmann, J Wollenhaupt, et al.
Annals of the Rheumatic Diseases
|
November 19, 2008
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
R Fleischmann, J Vencovsky, R F van Vollenhoven, et al.
JAMA
|
September 21, 1991
The interferons. Mechanisms of action and clinical applications
S Baron, S K Tyring, W R Fleischmann, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 125) with videos related to
Sort By:
Page
of 13
The Journal of Pediatrics
|
August 25, 2019
Vascular Health of Children Conceived via In Vitro Fertilization
Wendy Y Zhang, Elif Seda Selamet Tierney, Angela C Chen, et al.
The Journal of Cell Biology
|
September 1, 1984
Abnormality of insulin binding and receptor phosphorylation in an insulin-resistant melanoma cell line
H U Haring, M F White, C R Kahn, et al.
Clinical Rheumatology
|
October 14, 2016
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
R Fleischmann, P J Mease, S Schwartzman, et al.
The Clinical Journal of Pain
|
October 19, 1999
Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain
M E Hale, R Fleischmann, R Salzman, et al.
Clinical Therapeutics
|
November 24, 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group
T J Schnitzer, K Truitt, R Fleischmann, et al.
Journal of the Association for Information Science and Technology
|
October 17, 2022
Trust in COVID-19 public health information
Nitin Verma, Kenneth R Fleischmann, Le Zhou, et al.
Gastroenterology
|
June 1, 1990
A report of three multiclinic trials evaluating arbaprostil in arthritic patients with ASA/NSAID gastric mucosal damage. The Upjohn Company Arbaprostil ASA/NSAID Gastric Mucosal Damage Treatment Study Groups
A R Euler, M Safdi, J Rao, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D van der Heijde, R Fleischmann, J Wollenhaupt, et al.
Annals of the Rheumatic Diseases
|
November 19, 2008
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
R Fleischmann, J Vencovsky, R F van Vollenhoven, et al.
JAMA
|
September 21, 1991
The interferons. Mechanisms of action and clinical applications
S Baron, S K Tyring, W R Fleischmann, et al.
Page
of 13